View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 26, 2015updated 22 Nov 2021 8:18am

Sucampo to acquire Japan’s R-Tech Ueno for $278m

Sucampo Pharmaceuticals has agreed to acquire Japan-based pharmaceutical firm R-Tech Ueno for around JPY33bn ($278m).

Sucampo Pharmaceuticals has agreed to acquire Japan-based pharmaceutical firm R-Tech Ueno for 33bn-yen ($278m).
Under the deal, R-Tech Ueno will receive $54m in cash and 2.5 million Sucampo shares.

As per terms of the deal, Sucampo will purchase 56% of the outstanding shares of R-Tech Ueno in the tender offer.

Sucampo has also signed an agreement with R-Tech Ueno’s founders and a related entity to acquire the remaining 44% interest of the company.

“This immediately accretive transaction accelerates Sucampo’s growth and delivers on our strategic objectives of strengthening our financial performance and diversifying and expanding our product development pipeline.”

Sucampo CEO Peter Greenleaf said: “This immediately accretive transaction accelerates Sucampo’s growth and delivers on our strategic objectives of strengthening our financial performance and diversifying and expanding our product development pipeline.”

R-Tech Ueno produces Amitiza (lubiprostone) for Sucampo and Sucampo’s commercialisation partners, Mylan and Harbin Gloria Pharmaceuticals.

Amitiza is a prostone and locally acting chloride channel activator that is used in the US to treat CIC in adults and OIC in adults with chronic, non-cancer pain (24mcg twice daily).

It is also indicated in the US for irritable bowel syndrome with constipation (8mcg twice daily) in women 18 years of age and older in the US.

In Japan, Amitiza (24mcg twice daily) is prescribed to treat chronic constipation (excluding constipation caused by organic diseases).

In the UK, Amitiza is given (24mcg twice daily) to treat CIC and associated symptoms in adults, when response to diet and other non-pharmacological measures are inappropriate.

In Switzerland, it is indicated to treat CIC in adults and for the treatment of OIC and associated signs and symptoms such as stool consistency, straining, constipation severity, abdominal discomfort, and abdominal bloating in adults with chronic, non-cancer pain.

R-Tech Ueno also secures revenue from sales of Rescula (unoprostone isopropyl) in Japan.

In addition, the firm includes a wide range of drug candidates in various stages of development in gastroenterology, ophthalmology, autoimmune and inflammatory diseases and oncology.

The deal is expected to complete in the fourth quarter of this year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU